FindTrial
Sign In

A study to see the efficacy of injection vitamin D3 given into the skin warts.

Therapeutic efficacy of intralesional vitamin D3 in verruca vulgaris.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/04/018822
Enrollment
40
Registered
2019-04-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B079- Viral wart, unspecified

Interventions

Intervention1: Intralesional Vitamin D3: 0.2 ml (1,20,000 IU ) vitamin D3 solution will be slowly injected into the base of each wart. A maximum of 5 warts will be injected per se

Sponsors

Department of Dermatology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All untreated consecutive patients of verruca vulgaris. 2. Above the age of 14 years.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating females. 2. Any evidence of immunosuppression including HIV . 3. With a prior history of hypersensitivity to Vitamin D. 4. History of intake of vitamin D3, anabolic steroids or bisphosphonates in the last 3 months. 5. Patients having any significant systemic illness. 6. Patients having pre procedure serum vitamin D levels >100 ng/ml.

Design outcomes

Primary

MeasureTime frame
Therapeutic efficacy of intralesional vitamin D3 in verruca vulgarisTimepoint: 0,1,2,3,8 weeks—

Secondary

MeasureTime frame
Adverse effects of intralesional vitamin D3 in patients of verruca vulgaris.Timepoint: 0,1,2,3,8 weeks;Recurrence rate of verruca vulgaris treated with intralesional vitamin D3Timepoint: 8 weeks—

Countries

India

Contacts

Public ContactDr Surbhi Jain

Government Medical College and Hospital , sector 32 Chandigarh

thamigp@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026